Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19).
Ulf PetrauschMartin SpahnMartina SchneiderStefanie HayozCyrill A RentschSacha RothschildAurelius OmlinRichard CathomasPublished in: BMJ open (2023)
NCT04630730.